A recent study in patients with melanoma treated with combined immune checkpoint blockade (CICB) targeting CTLA-4 and PD-1 who developed ≥ grade 3 colitis demonstrates an intestinal overexpression of IL1β and TNF compared to normal tissue (96). This evidence concerns the gene TNF and melanoma.